SK biopharm is a global pharmaceutical company focused on the research, development, and commercialization of drugs, primarily in the central nervous system (CNS) and oncology sectors. The company’s core product is cenobamate, an antiepileptic drug marketed as XCOPRI in the United States and ONTOZRY in Europe, which is sold directly in the US through its subsidiary SK Life Science, Inc. and licensed to partners in other regions. SK biopharm also developed solriamfetol, a wakefulness-promoting agent marketed as SUNOSI, which is commercialized by partners such as Axsome Therapeutics. The company is expanding its pipeline into radiopharmaceutical therapy and targeted protein degradation, having acquired SK Life Science Labs to secure targeted protein degradation capabilities. SK biopharm licenses its drug candidates to partners in Europe, Asia, Canada, Latin America, and the Middle East, including Arvelle, Otsuka Pharmaceutical, Ignis Therapeutics, Endo Operations, Dexcel, Eurofarma, Hikma MENA, and Dong-A ST. The company collaborates with SK Biopharmaceuticals for the supply of active pharmaceutical ingredients and contract manufacturing services.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage skbp.com
Sector Healthcare IR page —
Tags
central nervous system, epilepsy, sleep disorders, radiopharmaceutical therapy, targeted protein degradation, oncology, neurology, psychiatry, innovative drugs, license-out, clinical development, XCOPRI, ONTOZRY, SUNOSI, cenobamate, solriamfetol, carisbamate, SKL13865, SKL20540, SKL24741, SKL35501, SKL37321, SK Life Science Inc., SK Life Science Labs Inc., SK Biopharmaceuticals, Axsome Therapeutics, Arvelle, Angelini, Otsuka Pharmaceutical, Ignis Therapeutics, Endo Operations, Knight Therapeutics, Dexcel, Eurofarma, Hikma MENA FZE, Dong-A ST, LifeSci Venture Partners, Mentis Care, Medsyn, Jazz Pharmaceuticals, Aerial Biopharma, Paladin Labs
Press page —

Metrics

Valuation  
Market cap ₩ 6.179T
Market cap (USD) $ 4.547B
P/E 15.41
PEG —
P/BV 6.05
P/S 7.17
P/OCF 24.87
P/FCF 25.67
Dividend yield —
Turnover / mcap —
Returns  
ROE 39.3%
ROI 32.8%
ROIC 25.1%
Profit margin 37.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 706.741B 547.596B 354.892B 246.179B 418.645B 25.999B 123.852B 1.099B
Net profit 266.95B 240.738B -35.379B -139.431B 64.846B -247.414B -71.519B -138.096B
Free cash flow 169.442B 93.505B -96.586B -164.831B -97.188B -221.749B -94.534B -142.717B

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) — 189M 8.56B 55.9B 63.5B 111B 174B 229B
↳ YoY growth +4,420.2% +552.6% +13.6% +74.8% +56.6% +31.6%
↳ 5y CAGR +291.3% +92.9%
Other receivables (KRW) 1.2B 759M 2.56B 900M 124M 2.22B — —
Borrowings, current (KRW) — 100B — — — 50B 151B 0.00
Borrowings, non-current (KRW) — — — — 144B 94.5B 0.00 0.00
Lease liabilities (KRW) — 9.06B 18.5B 15.7B 12.2B 33.6B 33.8B 48.9B
Cash and deposits (KRW) 74.3B 51.1B 59.3B 226B 104B 240B 323B 308B
Intangible assets (KRW) 246M 883M 19.7B 18.9B 17.2B 27B 32.5B 51.2B
Right-of-use assets (KRW) — — — — 12.4B 34.1B 31.9B 45.6B
Net debt (borrowings + leases - cash) (KRW) — 57.9B — — 51.8B -61.6B -289B -259B
Cash flow detail
Operating cash flow (KRW) -141B -81.3B -211B -92.9B -160B -94.2B 94.9B 176B
Purchases of property, plant and equipment (KRW) -1.44B -13.2B -11B -4.32B -4.91B -2.39B -1.4B -6.89B
Purchases of intangible assets (KRW) — -848M -3.31B -1.68B -1.05B -864M -12B -22.6B
Interest paid (cash effect) (KRW) — -1.23B -4.44B -844M -3.49B -8.14B -9.5B -6.44B
Income taxes paid (cash effect) (KRW) -36M -708M -6.39B -6.16B -4.68B -8.13B -12.2B -20B
Free cash flow (OCF - PPE - intangibles) (KRW) -143B -95.4B -225B -98.9B -166B -97.5B 81.5B 147B
Income detail
Total comprehensive income (KRW) -139B -71.7B -253B — -128B -34.8B 253B 252B
Comprehensive income to owners (KRW) — — — — -128B -32.9B 263B 267B
Reported Mar 16, 2021 Mar 16, 2021 Mar 16, 2021 Mar 18, 2024 Mar 18, 2025 Mar 18, 2025 Aug 14, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

SK biopharm (ticker 326030), listed in South Korea.

ETFs Holding SK biopharm

ETF Weight in ETF Shares Market value As of
DFSE 0.03% 2,524 $ 166.186K Nov 12, 2026
DEHP 0.02% 1,469 $ 96.722K Nov 12, 2026
DFAE 0.01% 17,954 $ 1.182M Nov 12, 2026
AVSE 0.01% 295 $ 19.25K Nov 16, 2026
AVXC 0.01% 329 $ 21.468K Nov 16, 2026
DFAX 0.01% 13,649 $ 898.683K Nov 12, 2026
DFEM 0.01% 9,127 $ 600.943K Nov 12, 2026
DEXC 0.00% 143 $ 9,415.46 Nov 12, 2026
AVEM 0.00% 3,545 $ 231.322K Nov 16, 2026